Nosopharm Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Liquidation
Nosopharm General Information
Description
Developer of anti-infective drugs designed to treat hospital-acquired infections. The company's drugs offer odilorhabdins which is a novel class of antibiotics that targets the multidrug-resistant based on the exploitation of microbial biodiversity for pharmacological applications, enabling patients to reduce the risk of infections.
Contact Information
Website
www.nosopharm.comCorporate Office
- 21 avenue Georges Pompidou
- Danica B
- 69486 Lyon
- France
Corporate Office
- 21 avenue Georges Pompidou
- Danica B
- 69486 Lyon
- France
Nosopharm Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Bankruptcy: Liquidation | 22-Jun-2024 | Completed | Bankruptcy: Liquidation | |||
| 6. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 5. Accelerator/Incubator | 28-Mar-2023 | Completed | Startup | |||
| 4. Later Stage VC | 17-Jul-2020 | Completed | Pre-Clinical Trials | |||
| 3. Debt - General | 12-Feb-2018 | Completed | Pre-Clinical Trials | |||
| 2. Later Stage VC | 28-Mar-2017 | $2.53M | $2.53M | Completed | Pre-Clinical Trials | |
| 1. Grant | 07-Nov-2013 | $2.59M | Completed | Startup |
Nosopharm Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| ABSA B-2020 | ||||||||
| Class A Prefered Shares | ||||||||
| Class A Prefered Shares | 336,349 | $1.126858 | $7.47 | $7.47 | 1x | $7.47 | 26.14% |
Nosopharm Comparisons
Industry
Financing
Details
Nosopharm Competitors (44)
One of Nosopharm’s 44 competitors is NovaBiotics, a Venture Capital-Backed company based in Aberdeen, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NovaBiotics | Venture Capital-Backed | Aberdeen, United Kingdom | ||||
| Cerecin | Venture Capital-Backed | Broomfield, CO | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Eternygen | Venture Capital-Backed | Berlin, Germany | ||||
| Alopexx | Corporation | Cambridge, MA |
Nosopharm Patents
Nosopharm Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024200838-A1 | New odilorhabdins analogues as antibiotics against multi-resistant bacteria | Inactive | 31-Mar-2023 | ||
| WO-2021148594-A1 | Chemical synthesis of the peptidic part of bioactive natural products | Inactive | 23-Jan-2020 | ||
| AU-2015323713-A1 | Novel peptide derivatives and uses thereof | Active | 26-Sep-2014 | ||
| AU-2015323713-B2 | Novel peptide derivatives and uses thereof | Inactive | 26-Sep-2014 | ||
| EP-3197908-A1 | Novel peptide derivatives and uses thereof | Pending | 26-Sep-2014 | C07K7/06 |
Nosopharm Signals
Nosopharm FAQs
-
When was Nosopharm founded?
Nosopharm was founded in 2009.
-
Where is Nosopharm headquartered?
Nosopharm is headquartered in Lyon, France.
-
What is the size of Nosopharm?
Nosopharm has 7 total employees.
-
What industry is Nosopharm in?
Nosopharm’s primary industry is Drug Discovery.
-
Is Nosopharm a private or public company?
Nosopharm is a Private company.
-
What is Nosopharm’s current revenue?
The current revenue for Nosopharm is .
-
How much funding has Nosopharm raised over time?
Nosopharm has raised $5.6M.
-
Who are Nosopharm’s competitors?
NovaBiotics, Cerecin, Inovio Pharmaceuticals, Eternygen, and Alopexx are some of the 44 competitors of Nosopharm.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process